THALICARPINE - AN OVERVIEW

Contraindicated (1)bortezomib will boost the amount or outcome of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or average CYP2C19 inhibitors may possibly raise mavacamten systemic publicity, resulting in coronary heart failure resulting from systolic dysfunction.The square root of two may be the frequency ratio